Phibro Animal Health acquires Osprey Biotechnics

TEANECK, N.J. — Phibro Animal Health Corp. announced that it has acquired the business and assets of Osprey Biotechnics Inc., a privately held developer and marketer of innovative microbial products. Acquiring the Osprey business strengthens Phibro’s portfolio of nutritional specialty products and provides new opportunities in a fast-growing sector of the animal health industry, the company noted.

“Osprey is a great business run by people we deeply respect. This acquisition provides Phibro with new product opportunities and a cutting-edge organization with strong manufacturing capabilities,” said Jack Bendheim, Phibro’s chairman, president and CEO. “Osprey’s proven and ever-expanding library of microbial strains will serve as an excellent platform for growth within the animal health industry as well as in burgeoning agriculture adjacencies such as seed coatings.”

“We are excited to join the Phibro family,” said Lauren Danielson, CEO of Osprey. “Partnering with Phibro opens up even more opportunities for our business, as it allows us to leverage Phibro’s proven expertise in nutritional specialty products that help improve animal health, productivity and profitability. We are also excited about the ability to scale our fermentation capacity, utilizing Phibro’s current footprint, to further service our customers. The value of this transaction is a testament to the highly skilled, innovative and hard-working people of Osprey.”

“We welcome Osprey’s dedicated team of employees to Phibro, and we are thrilled that Osprey’s leadership of Lauren Danielson and Vince Scuilla will continue as leaders of our microbial business as we integrate Osprey into Phibro,” said Larry Miller, Phibro’s chief operating officer. “Our employees share similar values and have a shared vision for working collaboratively with customers to help identify and provide solutions. We value the longstanding strategic relationships Osprey has built with its many customers across multiple industries, and we look forward to continuing to develop and strengthen these partnerships.”

Phibro expects the transaction to be accretive to adjusted EBITDA (earnings before interest, tax, depreciation and amortization) and adjusted diluted EPS (earnings per share) for the fiscal year ending June 30, 2020. Phibro funded the acquisition through its existing credit facilities.

Watch this discussion.Stop watching this discussion.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd,
racist or sexually-oriented language.PLEASE TURN OFF YOUR CAPS LOCK.Don't Threaten. Threats of harming another
person will not be tolerated.Be Truthful. Don't knowingly lie about anyone
or anything.Be Nice. No racism, sexism or any sort of -ism
that is degrading to another person.Be Proactive. Use the 'Report' link on
each comment to let us know of abusive posts.Share with Us. We'd love to hear eyewitness
accounts, the history behind an article.